Search Results

You are looking at 1 - 10 of 508 items for :

  • "disease progression" x
Clear All
Full access

Yvonne A. Efebera and Nina Shah

until disease progression.” Although no randomized clinical trial has compared maintenance duration (ie, postinduction and postconsolidation), she said, the closest study is a joint effort between the Intergroupe Francophone du Myelome (IFM) trialists

Full access

Wei Wang, Guilin Tang, Tapan Kadia, Xinyan Lu, Yan Li, Lanshan Huang, Ximena Montenegro-Garreaud, Roberto N. Miranda and Sa A. Wang

12), the t(8;22)(p11.2;q11.2) translocation with the product of BCR-FGFR1 fusion is extremely rare. Its clinicopathologic features and the mechanisms underlying disease progression are not well characterized. Here we report a patient with t(8;22) (p

Full access

Annette M. Lim, Graham R. Taylor, Andrew Fellowes, Laird Cameron, Belinda Lee, Rodney J. Hicks, Grant A. McArthur, Christopher Angel, Benjamin Solomon and Danny Rischin

disease progression after radical chemotherapy. (B) FDG-PET scan 1 month after commencement of BRAF inhibitor therapy demonstrates a metabolic response in all sites of disease accompanied with a partial radiological response. (C) FDG-PET scan 2 months

Full access

Susan O'Brien, Ellin Berman, Joseph O. Moore, Javier Pinilla-Ibarz, Jerald P. Radich, Paul J. Shami, B. Douglas Smith, David S. Snyder, Hema M. Sundar, Moshe Talpaz and Meir Wetzler

the patient population who may be at high risk for disease progression. In the absence of these biologic assays, lack of disease progression is an important end point and, if quantified, may be the best indicator that TKI therapy is really impacting

Full access

Sierra Cheng, Matthew C. Cheung, Di Maria Jiang, Erica McDonald, Vanessa S. Arciero, Doreen Anuli Ezeife, Amanda Rahmadian, Alexandra Chambers, Kelley-Anne Sabarre, Ambika Parmar and Kelvin K.W. Chan

ratio for death (HR OS) are considered the reference standard. In the absence of HR OS, other efficacy endpoints are used to compute CBS in the following order: median overall survival (mOS), hazard ratio for disease progression (HR PFS), median

Full access

Jaideep Sandhu, Chongkai Wang and Marwan Fakih

. This report presents a 58-year-old man with HER2 -amplified, KRAS G12D–mutated mCRC treated with T-DM1 who experienced disease progression on standard chemotherapy with 5-FU, oxaliplatin, irinotecan, and TAS-102, as well as dual HER2 targeting with

Full access

Jing Xi, Aabha Oza, Shana Thomas, Foluso Ademuyiwa, Katherine Weilbaecher, Rama Suresh, Ron Bose, Mathew Cherian, Leonel Hernandez-Aya, Ashley Frith, Lindsay Peterson, Jingqin Luo, Jairam Krishnamurthy and Cynthia X. Ma

treatment landscape for HR+/HER2– MBC rapidly evolves, questions remain as to the optimal ordering of various treatment options and the efficacy of subsequent therapies post–disease progression while on a CDK4/6 inhibitor. An applied understanding of the

Full access

Harrys A. Torres, Parag Mahale, Boris Blechacz, Ethan Miller, Ahmed Kaseb, H. Franklin Herlong, Nathan Fowler, Ying Jiang, Issam I. Raad and Dimitrios P. Kontoyiannis

analysis revealed that those without G-1 infections (odds ratio, 7.2; 95% CI, 2.2–55.6; P <.001) were more likely to experience an SVR. Underlying Liver Disease Progression Kaplan-Meier curves were plotted to determine the probability of cirrhosis

Full access

Jeremy D. Kratz, Nataliya V. Uboha, Sam J. Lubner, Daniel L. Mulkerin, Linda Clipson, Yanyao Yi, Menggang Yu, Kristina A. Matkowskyj, Noelle K. LoConte and Dustin A. Deming

sites of metastases combined with size of metastases, has predicted worsened OS. 17 , 22 This study investigated the impact of sidedness on the response to anti-EGFR therapy in the late-line setting, defined after initial disease progression during

Full access

Erin Currin, Lanell M. Peterson, Erin K. Schubert, Jeanne M. Link, Kenneth A. Krohn, Robert B. Livingston, David A. Mankoff and Hannah M. Linden

; T3, at subsequent disease progression on endocrine therapy; and T4, at disease progression on chemotherapy, before initiation of diethylstilbestrol (DES). At T1, the arrow shows spinal metastasis at L1 with strong uptake at initial metastatic